Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with EC and Nab-paclitaxel in Neoadjuvant TNBC
NCT04809779Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in triple-negative breast cancer (TNBC), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Status: unknown.
02
Drugs
sintilimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04809779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04809779.